The global neurological biomarkers market is anticipated to grow at a CAGR of 12.4% during the forecast period (2023-2030). Neurological biomarkers assist in monitoring the progress of neurological disease and studying biological responses toward a treatment. Neurological biomarkers capture different characteristics of a disease such as pathogenicity and heterogeneity, which helps in the development of personalized treatment therapy. Rapid research, technological advances, and funding in the field of neurology have led to the introduction of novel biomarkers that are accurate, reliable, and sensitive. For instance, in 2022, Johns Hopkins University (Baltimore, Maryland), Howard Lederman, granted funding of $1.6 million over four years. Moreover, in 2022, Virginia Commonwealth University provided funding of $1.6 million for type-1 to establish biomarkers and clinical endpoints.
Browse the full report description of “Neurological Biomarkers Market Size, Share & Trends Analysis Report by Biomarker Type (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), and by End Users (Hospital, Clinical Diagnostic Centers, Research Organizations) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/neurological-biomarkers-market
In addition, key players such as C?N’s Diagnostics, Neurosteer Ltd., Proteome Sciences PLC, and others are adopting numerous strategies such as collaboration, and new product launches in the field of the neurological biomarker to remain competitive in the marketplace. For instance, in September 2022, Metabolomics firm Metabolon partnered with the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore (NTU Singapore) on the identification of biomarkers for a range of health conditions. Metabolon accesses data from an NTU Singapore-led population cohort study to identify biomarkers related to the prevention, diagnosis, and treatment of a range of conditions. Furthermore, in February 2023, C2N Diagnostics, LLC, announced it has received a $15 million program-related investment from GHR Foundation. This financing signifies the foundation’s deep commitment to the company and to reducing the global burden of Alzheimer’s disease through early detection and prevention. Through this funding, the company conducted additional clinical studies to continue building real-world evidence around the use of PrecivityAD and PrecivityAD2, blood tests in clinical care. The investment enables broader market access, expanded medical education, biomarker pipeline development, and infrastructure growth to facilitate global expansion.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Biomarker Type
o By Application
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Abbott Laboratories, Bio-Rad Laboratories Inc., Qiagen N.V., Quanterix, Thermo Fisher Scientific Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Neurological Biomarkers Market Report Segment
By Biomarker Type
By Application
By End User
Global Neurological Biomarkers Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/neurological-biomarkers-market